Actuate Therapeutics, Inc. - Common stock

Share · US0050831009 · ACTU (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Actuate Therapeutics, Inc. - Common stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

29.04.2026 13:43

Current Prices from Actuate Therapeutics, Inc. - Common stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	ACTU	USD	29.04.2026 13:43	2,82 USD	-0,08 USD -2,76 %
IEX	ACTU	USD	29.04.2026 13:33	2,90 USD	-0,005 USD -0,17 %

Share Float & Liquidity

Free Float 35,31 %

Shares Float 8,37 M

Shares Outstanding 23,71 M

Company Profile for Actuate Therapeutics, Inc. - Common stock Share

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.